FDA Brief

Warning letters Drugs

FDA warning letter to

Libby Laboratories, Inc.

High riskIssued Jun 27, 2025Posted Jul 8, 2025Center for Drug Evaluation and Research (CDER)

FDA warned Libby Laboratories of Berkeley, California, that its drug manufacturing violated CGMP, including releasing a hospital antiseptic without microbial testing.

What happened

FDA inspected Libby Laboratories' drug manufacturing facility at 1700 Sixth Street, Berkeley, California, from March 11 to 14, 2025. Investigators found the firm released batches of OTC sunscreen and an antiseptic labeled for hospital use, including a batch sent to a children's hospital, without testing them for objectionable microorganisms. FDA also found no identity testing of components, no check on whether suppliers' test results could be trusted, and use of water bought at a local grocery store that was checked only for color, odor and appearance.

What FDA found

  1. The firm released drug batches, including a hospital antiseptic used before surgery, without testing any batch to show it was free of harmful microorganisms.

    21 CFR 211.165(b)
  2. The firm did not run at least one identity test on each lot of each ingredient, and did not periodically verify that its suppliers' test results were reliable.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  3. The firm used water bought from a local grocery store as an ingredient and checked it only for color, odor and appearance, when drug manufacturing requires purified water that is routinely tested.

    USP General Chapter <1231>, cited in the letter
  4. The firm did not test each shipment of each lot of a high-risk ingredient for hazardous impurities using the USP limit test, impurities that FDA says have caused lethal poisonings worldwide.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  5. The firm did not adequately test an incoming active ingredient for a hazardous impurity that FDA says has caused lethal poisonings worldwide.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  6. The firm's quality systems as a whole were inadequate to meet CGMP.

    21 CFR parts 210 and 211

What FDA wants

FDA asks the firm to reply in writing within 15 working days describing what it has done to fix the violations and prevent recurrence, including full chemical and microbiological testing of retained samples of batches still on the U.S. market, a risk assessment for products within expiry that may contain the high-risk ingredient, and results of impurity testing within 30 calendar days. FDA also recommends engaging a qualified CGMP consultant.

Who should pay attention

  • hospitals and surgery centers that bought the antiseptic
  • brands that buy OTC sunscreen or other drugs from this contract manufacturer
  • drug makers that accept supplier certificates of analysis without identity testing

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. CNC Noodle Corporation

    FDA warned CNC Noodle Corporation that its Hayward, California noodle plant had insanitary conditions, no pathogen or allergen controls, and mislabeled products.

    High risk
  2. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  3. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  4. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk